Is there a role for rituximab in the treatment of idiopathic childhood nephrotic syndrome?

Pediatr Nephrol. 2007 Jun;22(6):893-8. doi: 10.1007/s00467-006-0427-5. Epub 2007 Feb 20.


We each have nephrotic patients who become steroid dependent and in whom multiple immunosuppressive agents are employed. There is a need to balance possible therapeutic benefits with drug toxicity. This case report describes such a patient, who has suffered from nephrotic syndrome for over 11 years and had become resistant to the usual therapies. He was therefore given a single dose of the anti-CD20 drug rituximab, to which he showed a prompt response, leaving him free of proteinuria for the past 10 months.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Child, Preschool
  • Disease-Free Survival
  • Drug Resistance
  • Glomerular Mesangium / chemistry
  • Glomerular Mesangium / ultrastructure
  • Humans
  • Immunoenzyme Techniques
  • Immunoglobulin A / analysis
  • Immunologic Factors / therapeutic use*
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Nephrotic Syndrome / drug therapy*
  • Rituximab
  • Treatment Outcome


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Immunoglobulin A
  • Immunologic Factors
  • Immunosuppressive Agents
  • Rituximab